Ovarian cancer cells pretreated with anti‐EGFR TKIs exhibit increased sensitivity toward NK cell‐mediated ADCC,[352] suggesting EGFR‐TKI treatment can modulate the tumor cell surface properties, making them more susceptible to NK‐cell‐mediated killing. Here, EGFR is linked to ovarian carcinoma.